A randomised, placebo-controlled trial of concurrent cediranib (AZD2171)(with platinum-based chemotherapy) and concurrent and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer

 

Trial Summary:

ICON6 is a randomised (2:3:3), three-arm, double-blind, placebo-controlled multicentre Gynaecological Cancer InterGroup trial. It is a phase III multistage trial of cediranib given in combination with platinum-based chemotherapy, and continued as maintenance therapy, in patients with relapsed platinum-sensitive ovarian cancer (defined as relapsed disease 6 or more months after completion of first-line treatment).

Supported By:

 

Eligibility:

Women with platinum-sensitive relapsed ovarian cancer

Registration ID:

ACTRN12610000160033

Participation:

International

Australian Lead Group:

ANZGOG

Status:

Follow-up

Activation Date:

1/01/2011

Chairs:

J Lederman (international), Michelle Vaughan (Australia)

Contact:

icon6.study@sydney.edu.au